1型糖尿病组合疾病修饰治疗加速临床开发的创新设计与后勤考虑
本文是一篇观点性文章,指出尽管胰岛素发现已百年,1型糖尿病(T1D)的日常管理仍具挑战,外周胰岛素给药导致肝脏胰岛素不足、胰高血糖素升高而外周组织胰岛素过量。文章提出通过创新试验设计、加强后勤协调以及利用监管指南来加速评估候选T1D疾病修饰疗法(DMT),尤其是组合疗法。
要点
- T1D疾病修饰疗法旨在保存或恢复功能性β细胞质量并控制自身免疫,从而简化外源性胰岛素需求。
- 组合DMT可能带来更有意义的临床获益,但尚无DMT获批上市,现有监管指南为降低开发风险提供机会。
- 采用创新试验设计、加强后勤协调和利用加速开发、组合疗法及适应性设计的监管指南可加速T1D DMT评估。
核心结论
- T1D开发生态系统可通过采用更创新的方法测试DMT来加速进展。
研究设计与样本
- 本文为观点性文章,概述了加速评估候选T1D DMT(包括组合疗法)的建议。
主要发现
- 即使使用闭环系统,T1D患者仍需频繁干预以调整胰岛素剂量或摄入碳水化合物来纠正不匹配。
- 外周胰岛素给药导致肝脏胰岛素不足和高胰高血糖素血症,而外周组织胰岛素过量相对于其在血糖稳态中的正常生理作用。
- 疾病修饰疗法可保存和/或恢复功能性β细胞质量并控制或纠正自身免疫,从而简化外源性胰岛素需求,降低疾病死亡率、发病率和管 burdens。
- 识别有效的T1D DMT已被证明复杂,但有一些共识认为需要组合DMT以获得更有意义的临床获益。
- 尚无DMT获批上市,但现有监管指南为进一步降低开发风险提供了机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has been 100 years since the life-saving discovery of insulin, yet daily management of type 1 diabetes (T1D) remains challenging. Even with closed-loop systems, the prevailing need for persons with T1D to attempt to match the kinetics of insulin activity with the kinetics of carbohydrate metabolism, alongside dynamic life factors affecting insulin requirements, results in the need for frequent interventions to adjust insulin dosages or consume carbohydrates to correct mismatches. Moreover, peripheral insulin dosing leaves the liver underinsulinized and hyperglucagonemic and peripheral tissues overinsulinized relative to their normal physiologic roles in glucose homeostasis. Disease-modifying therapies (DMT) to preserve and/or restore functional β-cell mass with controlled or corrected autoimmunity would simplify exogenous insulin need, thereby reducing disease mortality, morbidity, and management burdens. However, identifying effective DMTs for T1D has proven complex. There is some consensus that combination DMTs are needed for more meaningful clinical benefit. Other complexities are addressable with more innovative trial designs and logistics. While no DMT has yet been approved for marketing, existing regulatory guidance provides opportunities to further "de-risk" development. The T1D development ecosystem can accelerate progress by using more innovative ways for testing DMTs for T1D. This perspective outlines suggestions for accelerating evaluation of candidate T1D DMTs, including combination therapies, by use of innovative trial designs, enhanced logistical coordination of efforts, and regulatory guidance for expedited development, combination therapies, and adaptive designs.
引用
- Anderson RL, DiMeglio LA, Mander AP, et al. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care. 2022. PMID: 36150059. doi:10.2337/dc22-0308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。